First World Conference on Luteinizing Hormone in ART: a Flight of Discovery 27-28 May 2016 - Naples, Italy
Total Page:16
File Type:pdf, Size:1020Kb
INTERNATIONAL CONFERENCE FINAL PROGRAMME AND ABSTRACT BOOK First world conference on luteinizing hormone in ART: A flight of discovery 27-28 May 2016 - Naples, Italy Dear Colleagues, It is a great pleasure to welcome you to the First world conference on luteinizing hormone in ART: A flight of discovery. This is the first international conference to focus on LH and it is a unique opportunity for researchers and medical practitioners to become better acquainted with this expanding area and share their results and experience. Our goal is to offer a global and comprehensive update of the most recent results and developments in LH research; to this end, some of the world’s top experts are here to share their knowledge with you. As your hosts, we look forward to making this event scientifically rewarding for you. Welcome to Naples: we hope you enjoy your flight. Best Regards, Giuseppe De Placido Carlo Alviggi Sandro C. Esteves Federico II University Federico II University ANDROFERT - Andrology & Naples, Italy Naples, Italy Human Reproduction Clinic São Paulo, Brazil 1 First world conference on luteinizing hormone in ART: A flight of discovery Overview The role of luteinizing hormone (LH) during folliculogenesis has heightened curiosity for at least three decades. In particular, the scientific community is still divided over recognizing the relevance of LH containing drugs during controlled ovarian stimulation (COS). Availability of recombinant drugs has offered, for the first time, the opportunity to explore the role of the follicle stimulating hormone (FSH) and luteinizing hormone (LH) separately. Despite this opportunity, the role of recombinant LH is still a matter of debate. What recently emerged is that LH is actively able to improve the outcome of IVF in specific subgroup of patients, including advanced age women and the so-called “hypo-responders”. The latter group is represented by subjects that, despite being young, having normal ovarian reserve, and being classified as nomonadotrophic, show “slow” and sub-optimal response to conventional FSH doses. It was estimated that the profile of ovarian response is evident in 10-12% of women undergoing COS. More interestingly, the increase in ongoing pregnancy rates in these two subgroups of women does not seem to be correlated with the number of oocytes, suggesting that improvement in oocyte quality and/or extragonadal effects of LH could be implicated. Although a growing body of evidence is defining the role of LH during COS, clear guidelines and practical recommendations on this aspect are lacking. This conference will show evidence from basic science to clinical practice regarding the use of recombinant LH and will illustrate its possible benefits as well as its physiopathological mechanism. Guided by an expert, participants will grasp the rationale for using recombinant LH in assisted reproductive technology as well as understand the role of LH in human reproduction. Learning objectives By attending this live educational conference, participants will be able to: • Understand the physiology of LH and its role in ovulation induction • Grasp the state of the art regarding the use of recombinant LH use • Individualise groups of patients that required LH during stimulation protocols • Identify specific ovarian reserve markers and genotype polymorphism useful for tailoring treatments and choosing the best approach Target audience This programme is intended for clinicians, embryologists, biologists and scientists working in ART. 2 Honorary President Giuseppe De Placido Federico II University Naples, Italy Chairs Carlo Alviggi Federico II University Naples, Italy Sandro C. Esteves ANDROFERT - Andrology & Human Reproduction Clinic Campinas, Brazil Local scientific committee Coordinator Ida Strina Federico II University Naples, Italy Members Luisa Avino Federico II University Naples, Italy Alessandro Conforti Federico II University Naples, Italy Pasquale De Rosa Federico II University Naples, Italy Silvia Picarelli Federico II University Naples, Italy Roberta Vallone Federico II University Naples, Italy 3 CME Provider EXCEMED is a non profit foundation dedicated, since the last four decades, to the development of high-quality medical education programme all over the world. EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME ®) which states that continuing medical education must be balanced, independent, objective, and scientifically rigorous. Continuing medical education EXCEMED ( www.excemed.org ) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME ®) to provide the following CME activity for medical specialists. The EACCME ® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net The CME workshop “First world conference on luteinizing hormone in ART: A flight of discovery” held on 27-28 May 2016 in Naples, Italy, is designated for a maximum of 6 (six) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME ® credits are recognized by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME ® credit to AMA PRA category 1 credit, please contact the AMA. The CME conference has been designated for 1,8 Italian CME Credits . N. Event 150342 Ed. 1 - Provider Id n. 3255 from the Italian Ministry of Health . EXCEMED adheres to the principles of the Good CME Practice group (gCMEp). 4 GENERAL INFORMATION Language The official language of this conference is English. CME Provider EXCEMED - Excellence in Medical Education Senior Programme Manager: Chloé Xilinas T +39 06 420413 505 - F +39 06 420413 677 [email protected] Medical Advisor: Alessandro Conforti [email protected] For any logistic support please contact: Event Planet srl Project Coordinator: Morena Trematerra | Paola Federico T +39 (0)81.5529399 - F +39 (0)81.4206734 [email protected] Format This live educational event is accompanied by innovative technological tools allowing participants to express their own views and opinions through real-time surveys, discussions, questions cards and mobile application. Mobile application To stay up to date with all conference activities: Downlaod the LH2016 app on your smartphone or tablet √ Enter the invitation code printed on your badge √ Any questions? You can pose your questions on the: Question card √ Mobile app √ Follow us on: #LH2016 5 PROGRAMME Friday, 27 May 2016 Saturday, 28 May 2016 X. Xxx (Xxx) From 12.00 Registration Welcome lunch Session III Landing in the real world 13.30 Opening Chairs: S.K. Sunkara (UK) - F. Zullo (Italy) R. Fischer (Germany) Real-time voting app 13.40 Local welcome 08.45 L7: The European point of view G. De Placido (Italy) K. Bühler (Germany) 13.50 Introduction 09.10 L8: The Indian point of view C. Alviggi (Italy) - S.C. Esteves (Brazil) M. Banker (India) Session I Taking off from basic science 09.35 L9: The Latin America approach S.C. Esteves (Brazil) Chairs: A. Ferraretti (Italy) - M.A. Sirard (Canada) Revisiting real-time voting app Real-time voting app 10.00 Panel discussion 14.00 L1: Physiology of LH and differences with hCG M. Simoni (Italy) 10.45 Coffee break 14.25 L2: Polymorphisms of LH and its receptor Session IV What about next flights I. Huhtaniemi (UK) Chairs: N. Colacurci (Italy) - E. Porcu (Italy) 14.50 L3: Facts and myths on the “Liaisons dangereuses” between LH and Progesterone Real-time voting app C.Y. Andersen (Denmark) 11.15 L10: Matching patient and protocols in low Revisiting real-time voting app prognosis; is it possible? P. Humaidan (Denmark) 15.15 Panel discussion 11.40 L11: ESHRE Bologna criteria: where are we? 16.00 Coffee break N.P. Polyzos (Belgium) Session II Flying through literature 12.05 L12: The flip side of LH R. Fanchin (France) Chairs: R. Fischer (Germany) - A. La Marca (Italy) Revisiting real-time voting app Real-time voting app 12.30 Panel discussion 16.30 L4: Is there a role for LH in elderly patients? E. Bosch (Spain) 13.15 Concluding remarks 16.55 L5: LH in low prognosis patients 13.30 End of the conference C. Alviggi (Italy) Closing lunch 17.20 L6: LH in antagonist cycles; is the story really written? R. Orvieto (Israel) Revisiting real-time voting app 17.45 Panel discussion 18.30 End of the first day Legend: L : Lecture 7 DISCLOSURE OF FACULTY RELATIONSHIPS EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME ®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further,